Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Rare Disease Precision Panel > Fibrosis Cystic Precision Panel

Fibrosis Cystic Precision Panel

Cystic Fibrosis (CF) is the most common lethal inherited disease in white persons. It is a life-limiting autosomal recessive genetic disorder, with highest prevalence in Europe, North America and Australia.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Cystic Fibrosis (CF) is the most common lethal inherited disease in white persons. It is a life-limiting autosomal recessive genetic disorder, with highest prevalence in Europe, North America and Australia. The disease is caused by mutation of a gene that encodes a chloride-conducting transmembrane channel that regulates anion transport and mucociliary clearance in the airways and other exocrine glands. This leads to an exocrine gland dysfunction that involves multiple organ systems resulting in chronic respiratory infections, pancreatic enzyme insufficiency, infertility and associated complications in untreated patients. End-stage lung disease is the principal cause of death. Most of the carriers of the CF gene are asymptomatic, therefore the importance of prenatal diagnosis as well as parent screening can identify those patients at risk of transmitting the mutation to their offspring.   

  • The Igenomix Cystic Fibrosis Precision Panel can be used as a diagnostic and screening tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes. 

Indication

  • The Igenomix Cystic Fibrosis Precision Panel is indicated in those cases where there is a clinical suspicion of CF or family history of CF with or without the following manifestations:  
    • Meconium ileus 
    • Rectal prolapse 
    • Pancreatic insufficiency: fat-soluble vitamin deficiency, malabsorption of fats, proteins and carbohydrates 
    • Failure to thrive 
    • Foul-smelling flatus 
    • Recurrent abdominal pain and abdominal distention 
    • Chronic and recurrent cough 
    • Recurrent pneumonia  
    • Shortness of breath on exertion 
    • Upper respiratory tract infections 
    • Undescended testicles 
    • Infertility 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis and improve prognosis. 
  • Early initiation of treatment with a multidisciplinary team to maintain lung function, administering nutritional therapy to maintain adequate growth and manage complications. 
  • Risk assessment and genetic counselling of asymptomatic family members to identify the likelihood of the individual being affected by the disease or being a carrier. 
  • Factors to consider when deciding whether to have CF genetic testing. 

Genes & Diseases

Methodology

References

See scientific referrals

Davis, P., Drumm, M., & Konstan, M. (1996). Cystic fibrosis. American Journal Of Respiratory And Critical Care Medicine, 154(5), 1229-1256. doi: 10.1164/ajrccm.154.5.8912731 

Cystic Fibrosis Mutation Database: Statistics. (2021). Retrieved 19 February 2021, from http://www.genet.sickkids.on.ca/cftr/StatisticsPage.html  

Elborn J. S. (2016). Cystic fibrosis. Lancet (London, England), 388(10059), 2519–2531. https://doi.org/10.1016/S0140-6736(16)00576-6 

Cutting G. R. (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nature reviews. Genetics, 16(1), 45–56. https://doi.org/10.1038/nrg3849 

Hale, J., Parad, R., & Comeau, A. (2008). Newborn Screening Showing Decreasing Incidence of Cystic Fibrosis. New England Journal Of Medicine, 358(9), 973-974. doi: 10.1056/nejmc0707530 

Skov, M., Hansen, C. R., & Pressler, T. (2019). Cystic fibrosis – an example of personalized and precision medicine. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 127(5), 352–360. https://doi.org/10.1111/apm.12915 

Comeau, A., Accurso, F., White, T., Campbell, P., Hoffman, G., & Parad, R. et al. (2007). Guidelines for Implementation of Cystic Fibrosis Newborn Screening Programs: Cystic Fibrosis Foundation Workshop Report. PEDIATRICS, 119(2), e495-e518. doi: 10.1542/peds.2006-1993 

Moskowitz, S. M., Chmiel, J. F., Sternen, D. L., Cheng, E., Gibson, R. L., Marshall, S. G., & Cutting, G. R. (2008). Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetics in medicine : official journal of the American College of Medical Genetics, 10(12), 851–868. https://doi.org/10.1097/GIM.0b013e31818e55a2 

Culling, B., & Ogle, R. (2010). Genetic Counselling Issues in Cystic Fibrosis. Paediatric Respiratory Reviews, 11(2), 75-79. doi: 10.1016/j.prrv.2010.01.001 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information